Erlotinib, an EGF receptor inhibitor that can reduce liver fibrosis and the development of hepatocellular carcinoma, suppressed the increased expression of Emp1 in GSE27640 (Figure 3(b)). Here, EMP1 is linked to hepatocellular carcinoma.